Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Hepatitis C
October 15, 2020
Therapeutic strategies for chronic hepatitis C have evolved rapidly over recent years. Following the debut of Sovaldi in 2013, direct-acting
antiviral (DAA) combination regimens containing at least two modes of action (nucleotide NS5B inhibitors, NS5A inhibitors, and NS3/4A
protease inhibitors) have rapidly become the standard of care, replacing older interferon-based regimens. The drastic shift to DAA regimens is
due to their significant advances in cure rates (=95%), greatly improved tolerability profiles, and shortened treatment durations (down from 48
weeks to 8–12 weeks for most patients).
Since peaking in 2015, the sales value of the hepatitis C market has entered a protracted decline as intensifying competition has slashed treatment costs, and patient numbers have fallen sharply in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK). Despite significant improvements in patient access to treatment as payers lifted treatment restrictions in response to lower treatment costs, the patient pool is expected to continue to shrink as the influx of newly diagnosed patients fails to offset the high number of patients exiting the treatment algorithm due to cure. Thus, investment in initiatives to improve screening uptake and linkage to care will be critical in softening the pace of this decline.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Hepatitis C (HCV) (Antiviral)|